Phase II liver cancer study of Iparomlimab and Tuvonralimab enters not yet recruiting status — LiveFuture News
Open on LiveFuture.ai →

Phase II liver cancer study of Iparomlimab and Tuvonralimab enters not yet recruiting status

ClinicalTrials.gov now lists a PHASE2, not yet recruiting study of Iparomlimab and Tuvonralimab with local therapy for hepatocellular carcinoma with portal vein tumor thrombus.

ClinicalTrials.gov now lists a PHASE2 study of Iparomlimab and Tuvonralimab combined with local therapy for first-line treatment of hepatocellular carcinoma with portal vein tumor thrombus. The registry entry was published 2026-11-16T00:00:00+00:00, and the study is marked NOT_YET_RECRUITING, so this is a planning-stage update rather than a report of patient results.

For a general reader, the practical takeaway is simple: researchers are setting up a single-arm, exploratory trial to see how this combination is handled in a difficult liver cancer setting. The sponsor named in the registry is Fujian Cancer Hospital, and the study title makes clear that the treatment is intended as first-line therapy.

What the registry says about the study

The study uses one experimental arm labeled Experimental. Its intervention is QL1706 (Iparomlimab/Tuvonralimab), listed as a DRUG, and it is paired with local therapy. Because the allocation is NA, the registry does not describe a comparison group in this entry.

The primary outcome is Objective Response Rate. In plain language, that means the trial is designed to measure the percentage of participants who achieve a documented response, with that response maintained for at least 4 weeks and assessed per mRECIST. The time frame runs from first study treatment up to maximum 3 years of participant treatment, or until disease progression, withdrawal of consent, initiation of new anti-cancer therapy, or intolerable toxicity, whichever comes first.

Why the timing matters

The record also gives a primary completion date of 2030-03-01, marked ESTIMATED. That signals a long horizon before any outcome readout would be expected from this entry, and the registry itself says has_results is false.

That matters because the study is still at the earliest stage of visibility. For now, the only firm facts are that it exists, that it is not yet recruiting, and that it is positioned as an exploratory PHASE2 effort. No outcome can be drawn from the entry itself.

Part of a wider cancer-trial snapshot

This study also sits inside the active special event Cancer Breakthroughs. Within that wider set of registry observations, other cancer studies are also visible, but this entry stands on its own as a liver cancer trial focused on hepatocellular carcinoma with portal vein tumor thrombus.

A reader following the field should treat this as a registry marker of research movement, not proof of benefit. The useful next question is not whether the treatment works yet, but when the study begins recruiting and whether results are later posted.